Trial Information
Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer
Inclusion Criteria:
- Signed informed consent.
- At least 18 years of age.
- On tamoxifen for at least 3 months for adjuvant therapy.
- On a stable diet for past 1 week before blood sampling.
- Compliant with tamoxifen medication.
- Completed adjuvant chemotherapy and/or adjuvant radiation therapy.
Exclusion Criteria:
• Patients should not be on the list of medications for the last 1 week before accrual to
the study
Type of Study:
Observational
Study Design:
Observational Model: Case-Crossover, Time Perspective: Cross-Sectional
Outcome Measure:
To determine the steady state pharmacokinetics of tamoxifen and its metabolites
Safety Issue:
No
Principal Investigator
Chiung Ing Wong, MRCP, MB ChB
Investigator Role:
Principal Investigator
Investigator Affiliation:
National University Hospital, Singapore
Authority:
Singapore: Domain Specific Review Boards
Study ID:
BR02/06/06
NCT ID:
NCT00717015
Start Date:
November 2005
Completion Date:
Related Keywords:
- Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Breast Neoplasms